Palo Alto Networks Up Over 7%, on Pace for Largest Percent Increase in Almost a Year — Data Talk
Palo Alto Networks, Inc. (PANW) is currently at $369.59, up $26.23 or 7.64%
--Would be highest close since Feb. 12, 2024, when it closed at $371.97
--On pace for largest percent increase since Aug. 21, 2023, when it rose 14.84%
--Currently up five of the past six days
--Currently up two consecutive days; up 10.62% over this period
--Best two day stretch since the two days ending Feb. 27, 2024, when it rose 11.58%
--Up 13.81% month-to-date
--Up 25.33% year-to-date
--Down 1.94% from its all-time closing high of $376.90 on Feb. 9, 2024
--Up 57.57% from 52 weeks ago (Aug. 22, 2023), when it closed at $234.56
--Down 1.94% from its 52-week closing high of $376.90 on Feb. 9, 2024
--Up 63.15% from its 52-week closing low of $226.53 on Sept. 25, 2023
--Traded as high as $369.95; highest intraday level since Feb. 16, 2024, when it hit $370.99
--Up 7.74% at today's intraday high; largest intraday percent increase since Feb. 27, 2024, when it rose as much as 8.19%
--Best performer in the S&P 500 today
--Best performer in the Nasdaq 100 today
--Eighth most active stock in the Nasdaq 100 today
All data as of 10:32:39 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 20, 2024 10:50 ET (14:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks